Haemopoietic Growth Factors

Postgraduate Haematology: Fifth Edition

Volumn , Issue , 2007, Pages 303-317

  Byrne, Jenny L ^a   Russell, Nigel H ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Erythropoietin; Growth factor receptors; Haemopoiesis; Jak stat signalling; Myelodysplasia

Indexed keywords

EID: 78049462365     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987056.ch18     Document Type: Chapter

References (36)

1. ASCO (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors:evidence-based clinical practice guidelines. Journal of Clinical Oncology 12: 2471-508.
2. ASCO (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. Journal of Clinical Oncology 14: 1957-60.
3. Basu S, Dunn A, Ward A (2002) G-CSF: function and modes of action (review). International Journal of Molecular Medicine 10:3-10.
4. Bearpark A, Gordon M (1989) Adhesive properties distinguishing subpopulations of haemopoetic stem cells with different spleen colony forming and marrow repopulating capacities. Bone Marrow Transplantation 4: 625-8.
5. Bensinger W, Martin P, Storer B et al. (2001) Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with haematologic cancers. New England Journal of Medicine 344: 175-81.
6. Blaise D, Kuentz M, Fortanier C et al. (2000) Randomised trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukaemia: a report from the Societe Francaise de Greffe de Moelle. Journal of Clinical Oncology 18: 537-546.
7. Bowen D, Culligan D, Jowitt S et al. (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndrome. British Journal of Haematology 120: 182-200.
8. Brenner M (ed.) (1994) Cytokines and Growth Factors. Baillière Tindall, London.
9. Broudy V (1997) Stem cell factor and haemopoiesis. Blood 90:1345-64.
10. Byrne JL, Haynes AP, Russell NH (1996) Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. Blood Reviews 11: 16-27.
11. Casadevall N, Nataf J, Viron B et al. (2002) Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. New England Journal of Medicine 346:1584-6.
12. Cazzola M, Mercuriali F, Brugnara C (1997) Uses of recombinant erythropoietin outside the setting of anaemia. Blood 89: 4248-67.
13. Freedman MH, Aler BP (2002) Malignant myeloid transformation in congenital forms of neutropenia. Israeli Medical Association Journal 4: 1011-14.
14. Haynes AP, Russell NH (1996) Clinical use of haemopoietic growth factors. In: Recent Advances in Haematology (A Hoffbrand, ed.). Churchill Livingstone, London.
15. Hellstrom-Lindberg H, Gulbrandsen N, Lindberg G et al. (2003) A validated decision model for treating the anaemia of myelodysplastic syndrome with erythropoietin and granulocyte colonystimulating significant effects on quality of life. British Journal of Haematology 120: 1037-45.
16. Hochaus S, Wassmann B, Egerer G (1998) Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplantation 22: 625-30.
17. Holyoake T, Alcorn M (1994) CD34 positive haemopoietic cells:biology and clinical applications. Blood Reviews 8: 113-24.
18. Hubel K, Dale D, Liles W (2002) Therapeutic use of cytokines to modulate phagocytic function in the treatment of infectious diseases: current status of granulocyte-macrophage colonystimulating factor, macrophage colony-stimulating factor and interferon-gamma. Journal of Infectious Diseases 185: 1490-501.
19. Ihle J, Kerr IM (1995) Jaks and Stats in signalling by the cytokine receptor superfamily. Trends in Genetics 11: 69-74.
20. Kauchansky K (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86: 419-31.
21. Lee S, Radford J, Dobson L (1998) Recombinant human granulocyte colony stimulating factor (filgrastim) following high dose chemotherapy and peripheral blood progenitor cell rescue in high grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer 77: 1294-9.
22. Ludwig H, Rai K, Blade J et al. (2002) Management of diseaserelated anaemia in patients with multiple myeloma or chronic lymphatic leukaemia: epoetin treatment recommendations. The Haematology Journal 3: 121-30.
23. Mangi M, Newland AC (1999) Interleukin-3 in haematology and oncology; current state of knowledge and future directions. Cytokines and Cellular Molecular Therapy 5: 87-95.
24. Maxwell PH, Pugh CW, Ratcliffe PJ (2001) The pVHL-hIF1 system. A key mediator of oxygen homeostasis. Advances in Experimental Medical Biology 502: 365-76.
25. Nemuniatis J, Buckner CD, Singer JW et al. (1990) Use of recombinant GM-CSF in graft failure. Blood 76: 245-53.
26. Nemunaitis J, Anasetti C, Storb R (1992) Phase II trial of recombinant human GM-CSF in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 79: 2572-7.
27. Osterborg A, Brandberg Y, Molostova V et al. (2002) Randomised double blind placebo controlled trial of recombinant human erythropoietin in haematological malignancies. Journal of Clinical Oncology 20: 2486-94.
28. Ozer H, Armitage J, Bennett C et al. (2000) Update of recommendations for the use of haematopoietic colony stimulating factors:evidence-based clinical practice guidelines. Journal of Clinical Oncology 18: 3558-70.
29. Pagliuca A, Carrington PA, Pettengell R et al. (2003) Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology 123: 22-33.
30. Price T (2002) Granulocyte transfusion in the G-CSF era. International Journal of Haematology 76: 77-80.
31. Rizzo JD, Lichtin A, Woolf S et al. (2002) Use of epoetin in patients with cancer: evidence based clinical practice guidelines of the American Society of Haematology. Blood 100: 2303-20.
32. Russell NH, Gratwohl A, Schmitz N (1996) The place of blood stem cells in allogeneic transplantation. British Journal of Haematology 93: 747-53.
33. Schmitz N, Linch DC, Dreger P et al. (1996) A randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347: 3563-3567.
34. Sheridan WP, Begley CG, Juttner CA et al. (1992) Effect of peripheral-blood progenitor cells mobilized by filgrastim (GCSF) on platelet recovery after high dose chemotherapy. Lancet 339: 640-4.
35. Storek J, Gooley T, Siadek M et al. (1997) Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease. Blood 90: 4705-9.
36. Stroncek D, Clay M, Petzoldt M et al. (1996) Treatment of normal individuals with granulocyte colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 36: 601-10.